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Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania trans-
mitted by insects of the genus Lutzomyia sp. or Phlebotomus sp. The main syndromes are
cutaneous leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis (kala-azar)
and post-kala-azar dermal leishmaniasis. This article reviews kidney involvement in cuta-
neous and visceral leishmaniasis, highlighting the aspects of their pathophysiology, clinical
manifestations, histopathological ﬁndings, outcome and treatment.Visceral leishmaniasis
American cutaneous leishmaniasis
Kala-azar
Kidney disease
©  2014 Elsevier Editora Ltda. All rights reserved.
In a recent study performed in our region, a total of 73
patients admitted with ACL were evaluated. Acute kidney
injury (AKI) was observed in 17 cases (23.2%), and oliguria wasIntroduction
Leishmaniasis is an infectious disease caused by protozoa
of the genus Leishmania transmitted by insects of the genus
Lutzomyia sp. or Phlebotomus sp.1 There are more  than 20
species of leishmanias causing clinical manifestations in
humans, and the main syndromes are cutaneous leishman-
iasis, mucocutaneous leishmaniasis, visceral leishmaniasis
(kala-azar), and post-kala-azar dermal leishmaniasis.2 This
article reviews kidney involvement in cutaneous and visceral
leishmaniasis.∗ Corresponding author at: Rua Vicente Linhares, 1198, 60135-270, Forta
E-mail addresses: geraldobezerrajr@yahoo.com.br (G.B. da Si
ef.daher@uol.com.br (E. De Francesco Daher).
http://dx.doi.org/10.1016/j.bjid.2013.11.013
1413-8670/© 2014 Elsevier Editora Ltda. All rights reserved.Cutaneous  leishmaniasis
Kidney  involvement  in  cutaneous  leishmaniasis
There have been few studies showing renal dysfunction in
American cutaneous leishmaniasis (ACL), which is, in some
cases, associated with the use of speciﬁc treatment with pen-
tavalent antimonial drugs.3,4leza, Ceará, Brazil.
lva Junior), elvino.barros@gmail.com (E.J. Guardão Barros),
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een in one case. Mean value of maximum serum creatinine
SCr) levels during hospital stay was 1.6 ± 0.6 mg/dL. Risk fac-
ors for AKI were advanced age, longer time between symptom
nset and hospital admission and longer hospital stay. Com-
lete renal function recovery was observed in 11 cases (64.7%)
t the time of hospital discharge.5 This same study found
rinary abnormalities, including proteinuria (4.1%), hema-
uria (4.1%) and leukocyturia (5.4%). Hypokalemia was found
n 12.3% of cases.5 Proteinuria and AKI had been previously
eported in other studies.6,7
Decreased urinary concentrating ability, with no reduction
f glomerular ﬁltration rate (GFR), was demonstrated by Veiga
t al.,8 who  studied an animal model of leishmaniasis treated
ith high doses of meglumine antimoniate. This abnormality
n urine concentration results from the action of antidiuretic
ormone (ADH) and also by a direct action of the drug in
ubular cells.8 High doses of antimonial drugs also cause a
eduction in GFR.
ACL is highly prevalent in the state of Ceará, Northeast
f Brazil. Low treatment adherence favors the development
f the mucocutaneous forms, which requires higher doses of
ntimonial drugs for longer periods, which, in turn, increases
ts toxicity even further. A recent study was performed in this
egion in order to investigate renal abnormalities in patients
ith ACL. Oliveira et al.9 studied 37 patients with conﬁrmed
iagnosis of ACL, performed urinary concentration and acid-
ﬁcation tests and also investigated the expression of urinary
xosomes in the urine of these patients.3 Urinary concen-
ration deﬁcit was found in 77% of cases. The expression
f aquaporin was signiﬁcantly reduced, while NKCC2 was
ncreased, in comparison to that in a control group. Urinary
cidiﬁcation deﬁcit was less frequent (40.5%). The expres-
ion of NHE3, H+-ATPase and pendrin was signiﬁcantly higher
mong patients than in controls.3 In this same cohort, a uri-
ary concentration deﬁcit was shown in 27 cases (77%) before
reatment with Glucantime®, while after treatment it was
bserved in 31 patients (88%) (p = 0.344). It is then possible that
CL can cause urinary concentration deﬁcit and speciﬁc treat-
ents do not decrease this defect, although it does not cause
igniﬁcant renal function impairment.
Combined defects (concentration and acidiﬁcation) were
een in 12 patients. Comparing the patients with and with-
ut tubular dysfunction, there were no differences regarding
ge, gender, time of disease, and number of cutaneous lesions.
here was no signiﬁcant abnormality regarding excretion frac-
ion of sodium, potassium, calcium and phosphate. There
as a signiﬁcant difference in serum magnesium concentra-
ions between patients with and without acidiﬁcation deﬁcit
2.15 ± 0.06 vs. 2.33 ± 0.04, p = 0.02). No patient with urinary
oncentration or acidiﬁcation deﬁcit had albumin/creatinine
atio >30 mg/g3.
Other infectious diseases with predominant involvement
f skin and nerves, such as leprosy, can also lead to glomerular
ysfunction. Oliveira et al.,9 in a prospective study with 59
atients with leprosy, showed decreased GFR in 50% of cases
hen considering GFR < 80 mL/min/1.73 m2, and in 5% when
2onsidering GFR < 50 mL/min/1.73 m .
Microalbuminuria is a known marker of glomerular
ysfunction in diabetes mellitus10 and also in cardiovas-
ular diseases.11,12 Microalbuminuria higher than 30 mg/g4;1 8(4):434–440 435
creatinine was observed in 35% of patients with ACL followed
in a health center in the state of Ceará, Brazil, before speciﬁc
treatment, and in only 8% of patients after treatment,3 sug-
gesting the presence of incipient glomerular lesion induced
by ACL itself, without concomitant GFR decrease.
Urinary exosomes were also found to be altered in ACL.3
Some studies have shown that aquaporin-2 (AQP2) is excreted
in urine in the form of vesicles. Its amount correlates with
circulating levels, and is used in studies to investigate body
water balance.13,14 In the cohort of patients with ACL studied
by Oliveira et al.,3 an increased percentage of patients with
urine concentration deﬁcit was observed and this was asso-
ciated with lower expression of AQP2.3 The increase in the
expression of NKCC2 can occur as a compensatory mecha-
nism. Abnormalities in the transporters involved in acid–base
regulation were also observed, including an increased expres-
sion of NHE3 (proximal tubule), H-ATPase and pendrin (distal
tubule) in patients with ACL, which could explain the urinary
acidiﬁcation deﬁcit.3
Pentavalent antimonial drugs are rapidly eliminated
through the kidneys,15 so their use should be avoided in
patients with renal dysfunction, due to cardiotoxicity and
renal function worsening. Urinary concentrating defect has
also been described and the heavy metal used in antimonial
composition is the main factor responsible for the toxicity.16
AKI may be due to massive deposition of immune complexes
formed after Leishmania destruction by antimonial drugs, a
phenomenon similar to that of Herxheimer reaction.17 Sam-
paio et al.18 evaluated 11 patients with ACL who  received
a double dose of antimonials (40 mg  Sbv/kg/day for 30 days),
and observed that one patient developed AKI. Eight patients
showed a decrease in GFR after 30 days of treatment. They also
observed distal and proximal tubular dysfunction, evidenced
as a decrease in urinary concentration ability and increased
sodium excretion fraction.
Rarely, treatment with meglumine antimoniate can cause
AKI due to interstitial nephritis.16 At low doses and for a short
period, pentavalent antimonial shows low renal toxicity. In
ACL treatment, however, it is many  times necessary to use
higher doses of pentavalent antimonial, which increases tox-
icity.
Visceral  leishmaniasis
Visceral leishmaniasis is a chronic, lethal, parasitic disease,
caused by the Leishmania parasite, an intracellular protozoan.
A large spectrum of clinical manifestations accompanies
the Leishmania attack on reticuloendothelial tissues – liver,
spleen, bone marrow, lymph nodes, and the digestive sys-
tem. Symptoms range from irregular and recurrent fever
to pancytopenia, hemorrhagic spells, and liver and spleen
enlargement.19
Kidney involvement in chronic leishmaniasis is frequent
and associated with increased mortality. It is endemic in
southern Europe and in tropical and sub-tropical areas of
the globe, with a worldwide incidence of approximately 0.5
million cases/year.20 When untreated, its mortality rate can
reach 95%. Among the so-called tropical diseases, kala-azar
is one of the WHO’s priorities. Endemic in Brazil, its agent is
436  b r a z j i n f e c t d i s . 2 0 1 4;1  8(4):434–440
Table 1 – Reports of kidney involvement in visceral leishmaniasis (kala-azar).
Reference Number of cases Age (years) Sex Immunosuppression Kidney biopsy Clinical presentation
Duarte et al. (1983)37 21 No Interstitial nephritis
Dutra et al. (1985)38 7 No Diffuse proliferative
lesion
AKI
Proteinuria
Caravaca et al.
(1991)39
1 33 M No Interstitial nephritis AKI
Leblond et al.
(1994)40
1 16 F No Collapsing
segmental and focal
glomerular sclerosis
AKI
Proteinuria
Chaigne et al.
(2004)41
1 20 M No Necrotizing
segmental and focal
glomerular sclerosis
AKI
Nephrotic
syndrome
Kumar et al. (2004)33 1 29 F No Membranoproliferative
lesion
Fever
Navarro et al.
(2006)34
1 28 M HIV AA amyloid
glomerular deposits,
no mesangial
hyperplasia
Nephrotic
syndrome
AKI
Efstratiadis et al.
(2006)42
1 65 M No Chronic
tubulo-interstitial
nephritis,
arteriolosclerosis
AKI
Lima Verde et al.
(2007)32
50 18–55 M (83%) No No AKI (28%)
Concentration
defect (68%)
Acidiﬁcation
defect (64%)
Alex et al. (2008)43 1 32 F HIV Tubular atrophy,
interstitial ﬁbrosis,
mononuclear
inﬁltrate, mesangial
hyperplasia,
peritubular
Leishmania-loaded
histiocytes
Nephrotic
syndrome
Daher et al. (2008)44 57 28 ± 18 M (74%) No No AKI (26%)
Dettwiler et al.
(2010)45
1 69 M Kidney transplant l Moderate to severe
lymphocyte,
histiocyte and
plasma cell
interstitial
inﬁltrates;
Leishmania-loaded
macrophages
Acute
interstitial
nephritis
AKI
Oliveira et al.
(2010)29
224 15–84 M (77%) No No AKI (34%)
Suankratay et al.
(2010)46
1 37 M HIV Membranoproliferative
lesion
Nephritic/nephrotic
syndrome
Daher et al. (2011)26 14 18–64 M (57%) No No Concentration
defect (21%)
ciencM, male; F, female; AKI, acute kidney injury; HIV, human immunodeﬁ
Leishmania chagasi.  Humans are infected through the vector
insect, Lutzomyia longipalpis.21 Kala-azar diagnosis is con-
ﬁrmed by demonstrating the presence of the parasite in
tissues using Giemsa stain, in addition to detection of parasite
antigen K-39.19
Kidney  involvement  in  visceral  leishmaniasisPatients presenting with chronic kala-azar can have mild
proteinuria, microscopic hematuria and leukocyturia. Hypoal-
buminemia, hypergammaglobulinemia and increased plasmay virus.
levels of both IgG and b2-microglobulins were found in a
group of 55 patients with visceral leishmaniasis.22 Increased
albumin excretion has been observed in 44% of patients. Pro-
teinuria consisted predominantly of low molecular weight
protein fractions that migrated with alpha1, alpha2, beta,
and especially gammaglobulins. Urinary b2-microglobulin
excretion was elevated in all patients. Microalbuminuria
was  detected in more  than 40% of patients with vis-
ceral leishmaniasis, even in those with normal creatinine
levels.23 Interstitial nephritis with glomerular changes can be
seen. A mesangial proliferative lesion is often found, yet a
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embranoproliferative lesion is not rare.19 Additionally,
myloid deposits can occur in chronic disease. Yet, renal
nvolvement is usually mild and transitory. Loss of kidney
unction and urinary sediment changes have been reported
n visceral leishmaniasis. Prospective studies with kala-azar
atients have demonstrated hematuria, mild to moderate pro-
einuria, and increased urine leukocytes in over 50% of cases.24
 large, retrospective study demonstrated that more  than 11%
f patients with chronic Leishmania disease had decreased ﬁl-
ration rate at hospital admission – with anti-parasitic therapy,
hanges disappear. Table 1 depicts known kidney involve-
ent in kala-azar. Interestingly, hypoalbuminemia, polyclonal
ypergammaglobulinemia and leukopenia usually occur in
19hronic leishmaniasis.
Other less frequent disorders have been described in
isceral leishmaniasis, including hormone and electrolyte
bnormalities. In a study by Limar Verde et al., of 72 patients
ig. 1 – Kidney: glomerulonephritis pattern in dogs with naturall
ltrastructure. (1) Minor glomerular abnormalities. Glomerular, v
roplets in the cytoplasm of the podocytes (arrow). Foot process 
ocal, segmental glomerulosclerosis. Swelling and effacement of
lectron-dense particles from the glomerular capillary basement
embranoproliferative glomerulonephritis. Segmental thickenin
all. PAMS. Bar = 25 m;  (4) diffuse, mesangial proliferative glom
ar = 25 m;  (5) crescentic glomerulonephritis. Fibrocellular or ﬁb
AMS. Bar = 25 m;  and (6) chronic glomerulonephritis. Intense a
emnants in interstitial space. Bar = 350 m.
eprinted from Costa, et al., Veterinary Pathology 40(6):677–84. C
athology.474;1 8(4):434–440 437
with visceral leishmaniasis, plasma ACTH (corticotrophin)
was found to be signiﬁcantly higher among patients in com-
parison to normal subjects, as well as plasma renin activity.
Primary adrenal insufﬁciency was observed in half of the
patients: they showed low aldosterone/renin plasma ratio,
low daily urinary aldosterone excretion and low transtubular
potassium gradient. In the same study, all patients had normal
plasma ADH concentrations, hyponatremia, and high urinary
osmolality, and more  than half of the patients had low plasma
parathyroid hormone and hypomagnesemia. In another study
from the same group, of 55 patients with visceral leish-
maniasis and 20 normal individuals, hyponatremia and high
urinary sodium were detected in all patients, suggesting
persistent ADH secretion with no evidence of extracellular
volume depletion. Normal plasma ADH levels were observed
in kala-azar patients. The syndrome of inappropriate ADH
secretion could be responsible for these ﬁndings.25 Electrolyte
y acquired VL. Histopathology (light microscopy) and
isceral, and epithelial cell vacuolization and protein
effacement (arrowhead) can be seen. EM.  Bar = 500 m;  (2)
 visceral and epithelial cell foot processes. Absence of
 membrane. EM.  Bar = 2170 m;  (3) diffuse,
g and duplication of the peripheral glomerular capillary
erulonephritis. Normal glomerular capillary wall. PAMS.
rous proliferation occupying part of the Bowman’s space.
ctivity of ﬁbroblasts, collagen proliferation, and cell
opyright (2003) with permission from Veterinary
i s . 2 0438  b r a z j i n f e c t d 
disturbances found in patients with visceral leishman-
iasis include hyponatremia (94.6%), hypokalemia (26%),
hypochloremia (27.2%), hypocalcemia (32%), and hypomag-
nesemia (41.8%).22 Increased urinary excretion fraction of
sodium, potassium, chloride, calcium, inorganic phosphate
and uric acid was found in one-third of the patients. Urinary
excretion fraction of magnesium was high in all patients.22
Urinary concentration and acidiﬁcation defects were also
found in patients with visceral leishmaniasis.26
There are some differences between adults and children
with visceral leishmaniasis. The time between symptom onset
and beginning of treatment is usually longer in adults (89.5
vs. 48.5 days, p < 0.001). Treatment failure with glucantime is
more common in adults (17.6% vs. 8.8%, p = 0.008). AKI associ-
ated with visceral leishmaniasis, which was observed in 37%
of cases, is more  severe in adults. Risk factors for AKI in adults
were hypokalemia, leukopenia, chills and amphotericin B use.
In children, secondary infections were found to increase the
27risk for AKI.
AKI can be found in a signiﬁcant proportion of patients
with visceral leishmaniasis.28,29 In a study of 146 children
with visceral leishmaniasis, AKI was found in 45.9% of cases.
Fig. 2 – Renal amyloidosis in a patient with visceral leishmanias
arrowhead; enlarged in (B)) and interstitial ﬁbrosis (white asteris
glomerular architecture by mesangial amyloid deposits; FAOG st
congophilic and produce apple-green birefringence; Congo red; 6
in the mesangium; transmission electron microscopy (uranyl ace
in capillary membranes in a subendothelial location; transmissi
Reprinted from de Vallière, et al., The American Journal of Tropic
with permission from The American Journal of Tropical Medicin 1 4;1  8(4):434–440
Patients in the AKI group were signiﬁcantly younger, and had
jaundice and secondary infections more  often than non-AKI
patients. The AKI group had signiﬁcantly lower serum sodium,
potassium, and albumin levels, elevated serum globulins and
a more  prolonged prothrombin time. The risk factors for AKI
were secondary infections (OR: 3.65, p = 0.007), serum albumin
decrement (OR: 1.672, p = 0.019), and high serum globulin (OR:
1.35, p = 0.029).28 In a study of 224 adults with visceral leish-
maniasis, AKI was observed in 33.9% of cases, and the risk
factors for AKI were male gender (OR: 2.2; p = 0.03), advanced
age (OR: 1.05; p < 0.001), and jaundice (OR: 2.9; p = 0.002).
Table 1 summarizes previous reports on kidney involve-
ment in visceral leishmaniasis.
Pathophysiology
Most parasitic diseases evolve into chronic illness, with ﬂuc-
tuations in antigenemia and host response. There are several
possible explanations, such as low natural immune response
or the parasite’s ability to evade the host immune system
attack. It has been demonstrated that development of host
resistance is usually dependent upon T-CD4+ cells producing
is and HIV. (A) Abundant mesangial amyloid deposits (black
k); FAOG stain; 100×, (B) almost complete obliteration of the
ain; 600×, (C) amyloid deposits in arteriolar wall that are
00×, (D) typical ultrastructural appearance of amyloid ﬁbrils
tate and lead citrate), and (E) amyloid ﬁbrils are also seen
on electron microscopy (uranyl acetate and lead citrate).
al Medicine and Hygiene 81(2):209–12. Copyright (2009)
e and Hygiene.35
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nterferon gamma (IFN) – a TH1-type cell. However, a mixed
H1 and TH2 response seems to be involved in extracellular
arasite eradication.30 The Leishmania is able to manipulate
he host immune system by inducing the production of growth
actor b, a macrophage-inhibiting cytokine, and interleukin-
0, besides interfering in IFN-gamma signaling, all of which
ffect cellular immune response and induce polyclonal B-cell
ctivation, which has been associated with kala-azar glomeru-
ar disease.30 Antibodies produced in response to infection
an be trapped in glomeruli by different mechanisms, such
s immune complexes, in situ development of complexes
antibodies linked to previously implanted glomerular anti-
ens), or directly attached to glomerular antigens. Yet, recent
tudies demonstrated that antibodies alone do not explain
he occurrence of proteinuria.30,31 Macrophages, granulocytes,
nd natural-killer lymphocytes are all part of host defenses,
nd participate in the genesis of glomerular lesions through an
ntricate chain of cytokines and inﬂammatory mediators, as
emonstrated experimentally.30,31 It is possible that reduced
ubular concentration and acidiﬁcation functions are caused
y IgG overload of tubular cells, in patients presenting with
ajor changes in plasma globulin levels.32 A distal tubule
cidiﬁcation defect can occur.
istopathology
esangial proliferative, membranoproliferative, and col-
apsing FSGS seem to be the patterns that are most
requently seen in association with kala-azar nephropathy,
he severity of which can vary from mononuclear intersti-
ial inﬁltration to a severe, diffuse, inﬂammatory inﬁltrate
onsisting of macrophages, lymphocytes and plasma cells.33
n immunoﬂuorescence microscopy, IgG, IgM, IGA and C3
eposits in the mesangial matrix can be found.33 Experi-
entally, tubular and interstitial lesions have been the most
requently seen kala-azar-associated kidney lesions. However,
myloid deposits and rapidly progressive glomerulonephri-
is with nephrotic syndrome have been reported in human
eishmaniasis.34,35 Experimental infection by L. donovani can
esult in amyloid deposition, following an initially diffuse pro-
iferative glomerular lesion.36 The ﬁnding of the amastigote
orms in the kidney is a rare event, yet it is possible to identify
eishmania antigens in inﬂammatory inﬁltrate.30 Figs. 1 and 2
llustrate the pathological ﬁndings in visceral leishmaniasis.
reatment
entavalent antimonial compounds are still the drugs of
hoice when treating visceral leishmaniasis. However, ampho-
ericin B might be equally effective. Kidney alterations usually
isappear soon after infection control.
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